1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Argenx SE
  6. News
  7. Summary
    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
Real-time Euronext Bruxelles  -  11:36 2022-06-24 am EDT
336.30 EUR   -1.09%
06/24Argenx Gets Positive CHMP Opinion for Generalized Myasthenia Gravis Drug
MT
06/24Argenx Gets EU Committee's Positive Opinion For Generalized Myasthenia Gravis Treatment
MT
06/24argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Decline in Thursday Trading

05/05/2022 | 11:49am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMARIN CORPORATION PLC -3.52% 1.92 Delayed Quote.-43.03%
ARGENX SE -1.09% 336.3 Real-time Quote.6.66%
AUTOLUS THERAPEUTICS PLC 2.80% 2.57 Delayed Quote.-50.48%
CREDIT SUISSE GROUP AG 5.15% 5.72 Delayed Quote.-35.53%
DBV TECHNOLOGIES -1.19% 4.476 Real-time Quote.46.32%
IDEX BIOMETRICS ASA -1.44% 1.167 Real-time Quote.-63.07%
IDEX CORPORATION 3.32% 185.56 Delayed Quote.-21.48%
LLOYDS BANKING GROUP PLC 2.61% 43.415 Delayed Quote.-9.17%
MATERIALISE NV 1.81% 14.61 Delayed Quote.-38.79%
MEREO BIOPHARMA GROUP PLC 8.51% 1.53 Delayed Quote.-4.38%
MIDATECH PHARMA PLC 0.00% 9.25 Delayed Quote.-49.32%
NATUZZI S.P.A. 3.08% 8.37 Delayed Quote.-47.46%
NATWEST GROUP PLC 1.60% 222.6 Delayed Quote.-1.37%
TC BIOPHARM (HOLDINGS) PLC 0.13% 0.3894 End-of-day quote.0.00%
VIA OPTRONICS AG 3.17% 2.6 Delayed Quote.-64.63%
WISEKEY INTERNATIONAL HOLDING AG 4.67% 0.28 Delayed Quote.-62.96%
All news about ARGENX SE
06/24Argenx Gets Positive CHMP Opinion for Generalized Myasthenia Gravis Drug
MT
06/24Argenx Gets EU Committee's Positive Opinion For Generalized Myasthenia Gravis Treatment
MT
06/24argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie..
GL
06/24Argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie..
AQ
06/17European ADRs Move Lower in Friday Trading
MT
06/15TRANSCRIPT : Argenx SE Presents at Goldman Sachs 43rd Annual Global Healthcare Conference,..
CI
06/07European ADRs Move Higher in Tuesday Trading
MT
06/03European ADRs Move Lower in Friday Trading
MT
06/01argenx to Present at Upcoming Investor Conferences
GL
06/01Argenx to Present at Upcoming Investor Conferences
AQ
More news
Analyst Recommendations on ARGENX SE
More recommendations
Financials
Sales 2022 171 M 181 M 181 M
Net income 2022 -937 M -988 M -988 M
Net cash 2022 1 439 M 1 518 M 1 518 M
P/E ratio 2022 -17,4x
Yield 2022 -
Capitalization 18 373 M 19 381 M 19 381 M
EV / Sales 2022 98,8x
EV / Sales 2023 35,8x
Nbr of Employees 650
Free-Float 100%
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 336,30 €
Average target price 357,45 €
Spread / Average Target 6,29%
EPS Revisions
Managers and Directors
Tim van Hauwermeiren Chief Executive Officer
Karl Gubitz Chief Financial Officer
Peter K. M. Verhaeghe Non-Executive Chairman
Hans J. W. de Haard Chief Scientific Officer
Luc Truyen Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ARGENX SE6.66%19 381
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574